It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been actively involved in shaping the guidance - and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance relating to:
* Regulatory and pharmacopoeial interpretation
* Valsartan update
* Purging update from Mirabilis consortium
* State of the art approaches to analysis of MIs
* How do I present my MI data in a regulatory submission?
This is an excellent opportunity to learn from expert speakers who have been actively involved in the development of the guidance on these key topics.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance relating to:
* Regulatory and pharmacopoeial interpretation
* Valsartan update
* Purging update from Mirabilis consortium
* State of the art approaches to analysis of MIs
* How do I present my MI data in a regulatory submission?
This is an excellent opportunity to learn from expert speakers who have been actively involved in the development of the guidance on these key topics.
